05 August 1995 00:00 [Source: ICB]
ZENECA HAS launched a treatment for advanced prostate cancer in its first market, the UK. The drug, Casodex, an oral anti-androgen, is licensed for use in combination with a luteinizing hormone releasing hormone analogue, such as Zeneca's Zoladex, or surgical castration.
The 1994 UK anti-androgen market was valued at £15m ($24m). Zeneca won UK marketing approval for Casodex late February, followed by approval in Ireland in April.
The company said in the UK half the 14 000 patients/year diagnosed with prostate cancer have advanced disease, and more than two-thirds of prostate cancers are hormone dependent and likely to respond to anti-androgens used in combination therapy.
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
Sample issue >>
My Account/Renew >>
Register for online access >>
|ICIS Top 100 Chemical Companies|
|Download the listing here >>|
Asian Chemical Connections